ArticleMedicine2025
Differentially expressed genes and therapeutic targets for nonalcoholic fatty liver disease from transcriptomic techniques.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver conditions globally. Lifestyle interventions are currently available as the main treatment modality. However, there is an urgent need to develop new therapeutic approaches for NAFLD owing to its complex pathological mechanisms. This study aimed to reveal potential therapeutic targets for NAFLD through molecular mechanism analysis. Using publicly available microarray datasets, we performed differentially expressed gene analysis to identify gene expression changes in NAFLD samples relative to healthy ones. Subsequently, expression-quantitative trait loci (eQTL) and Mendelian randomization (MR) analyses were applied to evaluate the relationship between these genes and NAFLD. Additionally, the potential functional pathways of differentially expressed genes were explored using enrichment analyses. A variety of differentially expressed genes are significantly up- or down-regulated in NAFLD samples. eQTL and MR analyses confirmed the causal relationship between some key genes and NAFLD. Enrichment analysis revealed that these genes are mainly associated with key signaling pathways, including inflammatory and immune responses, indicating that these pathways significantly contribute to the pathophysiology of NAFLD. This study revealed crucial genes and signaling pathways in NAFLD through multi-level bioinformatics and MR analysis, providing new insights for future treatments. The results underscore the necessity of comprehending NAFLD's intricate pathobiology to facilitate the development of innovative therapies, alleviate the burden on patients and society, and improve public health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.